Results 41 to 50 of about 5,430 (178)

Hepatitis C virus infection: Epidemiology in Egypt, Pathophysiology and DAAs-based therapy

Archives of Pharmaceutical Sciences Ain Shams University, 2021
Hepatitis C virus (HCV) was first identified in 1989. The situation in Egypt is really dire. The prevalence of HCV genotype 4 (GT-4) is 14.7%. About 10% of the middle-aged population (ages 15 to 59) is infected with HCV.
Heba Elbadawy, Sara Wahdan, Ebtehal El-Demerdash   +2 more
doaj   +1 more source

Daclatasvir sensitivity profile and validation.

, 2014
(A) A heat map shows the fitness landscape shift under Daclatasvir treatment (20 pM), which is calculated as the ratio of relative fitness scores (Wdrug/Wcontrol). The mutants that are lethal without drug are shown in grey. The secondary structure of DIA
Virginia Chu (549943), Shawna Truong (549944), James O. Lloyd-Smith (24136), Ren Sun (82856), Laith Q. Al-Mawsawi (307260), Nicholas C. Wu (549942), Claude Loverdo (434144), C. Anders Olson (549941), Sheng-Yao Su (368663), Roland Remenyi (270101), Chung-Yen Lin (10205), Zugen Chen (76247), Ruian Ke (102243), Ting-Ting Wu (1693231), Hangfei Qi (549940), Weidong Zhong (120728), Yushen Du (549945), Shu-Hua Chen (549946)   +17 more
core   +1 more source

Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection [PDF]

, 2022
BACKGROUND: The COVER trial evaluated whether nitazoxanide or sofosbuvir/daclatasvir could lower the risk of SARS-CoV-2 infection. Nitazoxanide was selected given its favourable pharmacokinetics and in vitro antiviral effects against SARS-CoV-2 ...
Johnstone, Hilary, Simmons, B, Sokhela, S, Hilary Johnstone, Joana Woods, Leah Ellis, Bosch, Bronwyn, Ellis, L, Andrew Owen, Owen, Andrew, Carmen Perez Casas, Johnstone, H, Hill, A, Casas, CP, Ellis, Leah, Woods, Joana, Bosch, B, Owen, A, Hill, Andrew, Simiso Sokhela, Woods, J, Willem Daniel Francois Venter, Bronwyn Bosch, Venter, WDF, Akpomiemie, Godspower, Bryony Simmons, Godspower Akpomiemie, Andrew Hill, Casas, Carmen Perez, Sokhela, Simiso, Venter, Willem Daniel Francois, Simmons, Bryony, Akpomiemie, G   +32 more
core   +1 more source

Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration [PDF]

, 2014
OBJECTIVES: Daclatasvir is a highly potent inhibitor of hepatitis C virus. We estimated the active tissue concentration of daclatasvir in vivo. METHODS: We developed a mathematical model incorporating pharmacokinetic/pharmacodynamic and viral dynamics ...
Sun, Ren, Loverdo, Claude, Lloyd-smith, James O., Qi, Hangfei, Lloyd-Smith, James O, Wu, Nicholas C., Olson, C Anders, Wu, Nicholas C, Olson, C. Anders, Ke, Ruian   +9 more
core   +2 more sources

The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients

Gut and Liver, 2018
Background/AimsAlthough daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed to evaluate the safety and efficacy of this
Shinya Taki, Hideyuki Tamai, Yoshiyuki Ida, Naoki Shingaki, Akira Kawashima, Ryo Shimizu, Kosaku Moribata, Takao Maekita, Mikitaka Iguchi, Jun Kato, Taisei Nakao, Masayuki Kitano   +11 more
doaj   +1 more source

Efficacy of Sovodak in the Management of Patients Co-infected with HIV/HCV [PDF]

Advanced Pharmaceutical Bulletin, 2020
Purpose: Sofosbuvir (SOF) and daclatasvir (DOC) are suggested for the treatment of hepatitis C virus (HCV) in patients with concomitant HCV and human immunodeficiency virus (HIV). In 2016, Sovodak tablet a combination of SOF and DOC was introduced.
Mohammad Hossein Somi, Bita Sepehri, Zeinab Nikniaz, Roya Sedghi   +3 more
doaj   +1 more source

Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans

Clinical Pharmacology &Therapeutics, EarlyView.
Genetic variation contributes substantially to interindividual and interpopulation differences in drug response, yet most pharmacogenomic studies remain biased toward European populations. Here, we systematically assessed pharmacogenomic variation across East Asians (EAS) and Europeans (EUR) using public genomic datasets and investigated the potential ...
Sihan Chen, Hongpu Chen, Shuhua Xu
wiley   +1 more source

Cyclodextrins as Chiral Selectors in Capillary Electrophoresis—Recent Developments in Understanding Analyte Complexation and Applications in Pharmaceutical Analysis

ELECTROPHORESIS, EarlyView.
Cyclodextrins are the most often applied chiral selectors in CE enantioseparations. In combination with NMR spectroscopy and molecular modeling, studies for an understanding of chiral recognition underlying enantioseparations have been performed.
Gerhard K. E. Scriba
wiley   +1 more source

Daclatasvir Prevents Hepatitis C Virus Infectivity by Blocking Transfer of Viral Genome to Assembly Sites.

, 2016
International audienceDaclatasvir is a direct-acting antiviral agent and potent inhibitor of NS5A, which is involved in replication of the hepatitis C virus (HCV) genome, presumably via membranous web shaping, and assembly of new virions, likely via ...
Boson, Bertrand, Chamot, Christophe, Denolly, Solène, Dreux, Marlène, Turlure, Fanny, François-Loïc, Cosset, Cosset, François-Loïc   +6 more
core   +1 more source

DEVELOPMENT AND VALIDATION OF A NEW RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION AND QUANTIFICATION OF SOFOSBUVIR AND DACLATASVIR

International Journal of Pharmacy & Integrated Health Sciences
Background: Sofosbuvir (SOF) and daclatasvir (DCV) are usually prescribed in combination for the treatment of hepatitis C worldwide. Objectives: In the present study a novel, simple, rapid, and cost-effective reversed-phase high performance liquid ...
Syed Hassan Murtaza, Ahmed Umer Sohaib Ahmed, Tassawer-e-Meran, Sonam Anees, Najam-ul-Hassan Khan, Kishwar Sultana   +5 more
doaj   +1 more source